Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

Despite Trump’s fervent claims that Greenland’s 55,000 residents desire to join the US, both Denmark and Greenland’s local ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity: Bagsværd, Denmark Monday, January 27, 2025, 13:00 ...

Coupled to that, inherent in the make-up of American versus foreign stocks, value stocks, meaning statistically cheaper on ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...